Three Main Causes of Homocystinuria: CBS, cblC and MTHFR Deficiency. What do they Have in Common?

Giovana Regina Weber Hoss1,2, Soraia Poloni1,2, Henk J Blom3, Ida Vanessa Doederlein Schwartz1

Abstract

Genetic homocystinurias are a group of inborn errors of metabolism that result in the massive excretion of homocysteine (Hcy) in the urine due to Hcy accumulation in the body, usually causing neurological and cardiovascular complications. The three most frequent causes are classical homocystinuria [deficiency of cystathionine beta-synthase (CBS)], methylmalonic aciduria with homocystinuria, cblC type (cblC deficiency) and severe methylenetetrahydrofolate reductase (MTHFR) deficiency. In this review, we highlight the similarities and differences among these disorders. Briefly, their joint manifestation is the accumulation of tHcy, however, the other sulfur amino acids show various and even invers profiles. Vascular disease, developmental delay and seizures are found in all homocystinurias, nevertheless, the complications of CNS differ in a wide variety of presentations and severities and are apparently less pronounced in CBS deficiency. Moreover, patients with remethylation defects typically do not present ectopia lentis and bone disturbances, tall stature and osteoporosis. Whereas hematological alterations, such as megaloblastic anemia, thrombocytopenia neutropenia and life-threatening microangiopathy, are specific findings of cblC deficiency.

Keywords

classical homocystinuria, methylmalonic aciduria with homocystinuria, cblC type, Severe MTHFR deficiency.

Background

Hyperhomocysteinemia (tHcy >15 μM)[1] can be caused by environmental (such as nutritional deficiency of vitamins B12 or folate) or genetic factors, including inborn errors of metabolism (Table 1). Mild or moderate forms of hyperhomocysteinemia are present in 5–10% of the population.[2] The severe form of hyperhomocysteinemia (tHcy>50 μM) is rare, and typically associated with severe vitamin B12 or folate deficiency or inherited defects in Hcy metabolism.[3] Total Hcy (tHcy) consists of free Hcy (reduced plus oxidized Hcy in the non-protein fraction of plasma) and protein-bound Hcy.

Hcy is a sulfur-containing amino acid not used in protein synthesis and is considered toxic at increased levels. Hcy is formed as a product of methyl-transfer reactions in methionine (Met) metabolism. In this process, Met is activated by ATP into S-adenosylmethionine (SAM), which is the universal methyl group donor, resulting in the formation of S-adenosylhomocysteine (SAH). SAH is converted to Hcy and adenosine through S-adenosyl-L-homocysteine hydrolase (SAHH). The equilibrium of the reaction favors the formation of SAH. As a consequence, increased Hcy should result in a pronounced accumulation of SAH, which is a potent inhibitor of many methyltransferase reactions. While methylation is essential for cellular functions in all organs, Hcy is formed in all tissues, but its elimination via CBS (EC 4.2.1.23), in the transsulfuration pathway, is considered to only occur in the liver and kidney.

1 Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil
2 Hospital de Clínicas de Porto Alegre, Porto Alegre, RS, Brazil
3 Department of Internal Medicine, University Medical Centre Amsterdam, Amsterdam, Noord-Holland, Netherlands

Received July 8, 2019, and in revised form September 13, 2019. Accepted for publication October 28, 2019.

Corresponding Author:
Giovana Regina Weber Hoss, Programa de Pós-Graduação em Genética e Biologia Molecular, Universidade Federal do Rio Grande do Sul, Porto Alegre, RS, Brazil.
Email: giovana.weber@gmail.com

This article is distributed under the terms of the Creative Commons Attribution 4.0 License (http://www.creativecommons.org/licenses/by/4.0/) which permits any use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SciELO and Open Access pages (http://www.scielo.br/jiems/).
Thus, in all other tissues, such as the vascular system and the brain, the only available possibilities to eliminate Hcy are remethylation by methionine synthase (MTR - EC 1.16.1.8) or exportation out of the cell.[4] In remethylation, Hcy receives a methyl group from 5-methyltetrahydrofolate (5MTHF), which is formed from 5,10-methylenetetrahydrofolate by MTHFR (methylenetetrahydrofolate reductase - EC 1.5.1.20) (Figure 1).

Notably, 5MTHF is the circulating form of folate in blood and cerebrospinal fluid (CSF).

The active elimination of Hcy from the body is the main regulator of Met and methylation homeostasis and occurs in the liver and kidney via degradation by CBS. The liver and kidney also contain betaine-homocysteine methyltransferase (BHMT - EC 2.1.1.5), which is an alternative way of Hcy remethylation (Figure 1). SAM is the main regulator of Met and methylation status. In the liver excess of Met increases SAM, causing Hcy to be mainly remethylated back to Met.[7,8] Vitamin B12, as methylcobalamin (Mecbl), is involved as a cofactor for MTR, which catalyzes the remethylation of Hcy into Met in the cytosol. Adenosylcobalamin (Adocbl) is the cofactor for methylmalonyl-CoA mutase, which converts methylmalonyl-CoA into succinyl-CoA in mitochondria (Figure 2). This paper reviews the clinical and biochemical findings and management of the three most frequent genetic causes of homocystinurias: CBS deficiency or classical homocystinuria (HCU), methylmalonic aciduria with homocystinuria cblC type, and severe MTHFR deficiency. These three disorders all present with severe hyperhomocysteinemia, while Met levels are increased in HCU and decreased or normal in cblC and MTHFR deficiency, and methylmalonic acid (MMA) is increased only in cblC[9] (Table 1). Folate and Hcy metabolism are intertwined. As a consequence, defects in Hcy metabolism influence folate homeostasis. In CBS deficient patients at diagnosis folate is often deficient likely due to the inhibition of MTHFR resulting in decreases of 5MTHF, the circulation form of folate. In MTHFR

<table>
<thead>
<tr>
<th>Disease (OMIM number)</th>
<th>Deficient Enzyme</th>
<th>Gene (Locus)</th>
<th>Pattern of Inheritance</th>
</tr>
</thead>
<tbody>
<tr>
<td>Classical homocystinuria (# 236200)</td>
<td>Cystathionine beta-synthase (CBS - EC 4.2.1.23)</td>
<td>CBS (21q22.3)</td>
<td>AR</td>
</tr>
<tr>
<td>Severe methylenetetrahydrofolate reductase (MTHFR) deficiency (# 236250)</td>
<td>Methyleneetetrahydrofolate reductase (MTHFR - EC 1.5.1.20)</td>
<td>MTHFR (1p36.22)</td>
<td>AR</td>
</tr>
<tr>
<td>Methylmalonic aciduria and homocystinuria, cblC type (# 277400)</td>
<td>Methylmalonyl-CoA mutase (MUT - EC 5.4.99.2) and methionine synthase (MTR - EC 1.16.1.8)</td>
<td>MMACHC (1p34.1)</td>
<td>AR</td>
</tr>
<tr>
<td>Methylmalonic aciduria and homocystinuria, cblC type, digenic (epi-cblC #277400)</td>
<td>Methylmalonyl-CoA mutase (MUT - EC 5.4.99.2) and methionine synthase (MTR - EC 1.16.1.8)</td>
<td>PRDX1 (1p34.1)</td>
<td>AR</td>
</tr>
<tr>
<td>Methylmalonic aciduria and homocystinuria, cblD type (# 277410)</td>
<td>Methylmalonyl-CoA mutase (MUT - EC 5.4.99.2) and methionine synthase (MTR - EC 1.16.1.8)</td>
<td>MMADHC (2q23.2)</td>
<td>AR</td>
</tr>
<tr>
<td>Homocystinuria-megaloblastic anemia, cblE type (# 236270)</td>
<td>Methylene synthase reductase (MTRR - EC 2.1.1.135)</td>
<td>MTRR (5p15.31)</td>
<td>AR</td>
</tr>
<tr>
<td>Methylmalonic aciduria and homocystinuria, cblF type (# 277380)</td>
<td>Methylmalonyl-CoA mutase (MUT - EC 5.4.99.2) and Methionine synthase (MTR - EC 1.16.1.13)</td>
<td>LMBRD1 (6q13)</td>
<td>AR</td>
</tr>
<tr>
<td>Homocystinuria-megaloblastic anemia, cblG type (# 250940)</td>
<td>Methylene synthase (MTR - EC 2.1.1.13)</td>
<td>MTR (1q43)</td>
<td>AR</td>
</tr>
<tr>
<td>Methylmalonic aciduria and homocystinuria, cblJ type (# 614857)</td>
<td>Methylmalonyl-CoA mutase (MUT - EC 5.4.99.2) and Methionine synthase (MTR - EC 2.1.1.13)</td>
<td>ABCD4 (1q24.3)</td>
<td>AR</td>
</tr>
<tr>
<td>Methylmalonic acidemia and homocystinuria, cblX type (# 309541)</td>
<td>Methylene synthase reductase (MTHFR - EC 2.1.1.13)</td>
<td>HCF1 (Xq28)</td>
<td>XLR</td>
</tr>
<tr>
<td>Methyleneetetrahydrofolate dehydrogenase (MTHF) deficiency (# 617780)</td>
<td>5,10-methylenetetrahydrofolate dehydrogenase (EC 1.5.1.5), 5,10-methylenetetrahydrofolate cyclodrolase (EC 3.5.4.9), and 10-formyltetrahydrofolate synthetase (EC 6.3.4.3)</td>
<td>MTHFD1 (1q23.3)</td>
<td>AR</td>
</tr>
<tr>
<td>Transcobalamin II (TC) deficiency (# 275350)</td>
<td>Transcobalamin; Cellular delivery of cbl. Methylmalonyl-CoA mutase (MUT - EC 5.4.99.2) and Methionine synthase (MTR - EC 1.16.1.8)</td>
<td>TCN2 (22q12.2)</td>
<td>AR</td>
</tr>
<tr>
<td>Methylmalonic aciduria and homocystinuria, TcblR type (# 613646)</td>
<td>TcblR; Cellular receptor for TC. Methylmalonyl-CoA mutase (MUT - EC 5.4.99.2) and Methionine synthase (MTR - EC 1.16.1.8)</td>
<td>CD320 (19p13.2)</td>
<td>AR</td>
</tr>
</tbody>
</table>

cbl = cobalamin, AR = autosomal recessive, XLR= X-linked recessive.
Figure 1. Overview of homocysteine metabolism. MAT: methionine adenosyltransferase; SAM: S-adenosylmethionine; SAH: S-adenosylhomocysteine; SAHH: S-Adenosyl-homocysteine hydrolase; CβS: cystathionine β-synthase; CγL: cystathionine γ-lyase; MTR: methionine synthase; THF: tetrahydrofolate; MTHFR: 5,10-methylene-THF reductase; SHMT: serine-hydroxymethyltransferase; BHMT: betaine-homocysteine methyltransferase; MMACHC: methylmalonic aciduria and homocystinuria type C protein; Enzymes are shown in capitals, and their cofactors in italics.

deficiency folate is severely deficient, whereas in cblC defect all folates accumulate as 5MTHF resulting in functional cellular folate deficiency.

Classical Homocystinuria

Clinical presentation

CBS deficiency or classical homocystinuria (HCU; OMIM +236200) is the most common type of homocystinuria. The prevalence of HCU dramatically varies between regions from 1:240 at the Orchid Island to less than one in one million in the Taiwanese Han population.[10] The worldwide prevalence is estimated at 1:100,000 to 1:344,000 individuals.[11,12]

Four organ systems are primarily affected in HCU: ocular, vascular, central nervous (CNS) and skeletal[13] (Table 2). The hallmark study of Mudd et al. in 1985 concerns a cohort of over 600 patients. According to this survey, eye disease, particularly lens dislocation (ectopia lentis), was the main reason for HCU investigation (85% of the cases) and commonly the first symptom, manifesting after the age of two years old and affecting more than 50% of non-treated patients at the age of 10 years old. [14] Other ocular abnormalities that might occur in HCU include high myopia, iridodonesis, glaucoma, optic atrophy, retinal degeneration, retinal detachment, cataracts and corneal abnormalities.[11,15–17]

Another common feature of HCU is vascular disease. Thromboembolic events can occur at any age and at any vein. [14,18–21] Although it is less common than eye disease, 50% of non-treated patients presented a thromboembolic event at age 29, and the importance of this disease is demonstrated by the high mortality rate from vascular complications. In Mudd’s survey[14], over 70% of the deceased patients died because of thromboembolism. Special circumstances, such as pregnancy, surgery and association with mutations in Factor V, seem to increase the risk of vascular events.[22–24] Interestingly, recent studies showed that vascular manifestations can be the sole symptom and can appear even after the second or third decade
Figure 2. Overview of B12 metabolism. MMA: methylmalonic acid; MUT: methylmalonyl CoA mutase; Mut -: partial loss of MUT function; Mut 0: complete loss of MUT function; Adocbl: adenosylcobalamin; cblI: cobalamin; MMAA: Methylmalonic aciduria type A; MMAB: Methylmalonic Aciduria cblB Type; MMADHC: methylmalonic aciduria and homocystinuria type D; MMACHC: methylmalonic aciduria and homocystinuria type C protein; LMBRD1: gene that encodes a lysosomal membrane protein that may be involved in the transport and metabolism of cobalamin affected in cblF; ABCD4: gene ATP binding cassette subfamily D member 4 related to cblJ; HCFC1: gene host cell factor C1 related to cblX; OH-cbl: hydroxocobalamin; CN-cbl: cyanocobalamin; TCN2: transcobalamin 2; MTRR: gene methionine synthase reductase related to cblE; Mecbl: Methylcobalamin and MTR: methionine synthase related to cblG.

of life, especially in patients homozygous for the CBS c.833 T>C (p.Ile278Thr) mutation.[18, 25]

Cognitive impairment is also considered a common CNS manifestation of HCU. In Mudd’s survey, a wide range of IQ’s from 10 to 138 was reported, with a median of 78.[14] A recent study from Qatar observed that patients early diagnosed by neonatal screening had significantly higher intelligence quotient, quality of life, and adherence to treatment when compared with the late diagnosed patients.[26] In addition to the direct toxicity of Hcy on CNS, recurrent strokes can also impact cognitive skills.[11,22] Seizures occur in nearly 20% of the patients.[14] Psychiatric disorders are also highly prevalent, affecting up to 50% of patients.[27] Schizophrenia, anxiety and depression are well documented in HCU.[11,27–30] The most common symptoms observed by Abbott et al., (1987) in 63 patients include episodic depression (10%), chronic behavior disorders (17%), chronic obsessive-compulsive disorder (5%), and personality disorders (19%).[27] Additionally, psychiatric disorder as an isolated symptom of HCU has been reported.[31, 32]

The skeletal features of HCU include osteoporosis and osteopenia, scoliosis, dolichostenomelia, tall stature, genu valgum, sternal deformities and arachnodactyly.[14,33] The most frequent finding is osteoporosis, which affects approximately half of non-treated patients in their second decade of life.[14] In addition to eye abnormalities (ectopia lentis), the bone deformities (with the exception of osteoporosis) resemble those observed in Marfan Syndrome, what has led to misdiagnosis in the past.[34] Other clinical findings reported in HCU include hypopigmentation of the hair and skin and malar flush, and there is a case report on acute pancreatitis and chronic diarrhea.[35–38]
**Table 2.** Biochemical presentation and clinical manifestation of non-treated homocystinuria disorders due to CBS, cblC and MTHFR defects

<table>
<thead>
<tr>
<th></th>
<th>CBS</th>
<th>cblC</th>
<th>MTHFR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Homocysteine</td>
<td>↑↑</td>
<td>↑↑</td>
<td>↑↑</td>
</tr>
<tr>
<td>Methionine</td>
<td>↑↑*</td>
<td>Normal or ↓</td>
<td>Normal or ↓</td>
</tr>
<tr>
<td>Cystathionine</td>
<td>↓↓*</td>
<td>↑↑</td>
<td>↑↑</td>
</tr>
<tr>
<td>Methylmalonic acid</td>
<td>Normal</td>
<td>↑↑**</td>
<td>Normal</td>
</tr>
<tr>
<td>Cysteine</td>
<td>↓↓</td>
<td>↓</td>
<td>↓</td>
</tr>
</tbody>
</table>

Clinical findings in common

- **Central nervous system**: Seizures, psychiatric disorders, mental retardation.
- **Cardiovascular, Vessels and hematology**: Thromboembolism

More specific clinical findings

- **Central nervous system**: Sequelae of thromboembolic events*.
- **Eye**: Ectopia lentis*, myopia* and glaucoma*.
- **Bone**: Normal to tall stature and generalized osteoporosis*.
- **Cardiovascular, Vessels and hematology**: Megaloblastic anemia**, thrombocytopenia** and neutropenia**.
- **Treatment**: Pyridoxine, folinic acid, dietary Met restriction, betaine, acetylsalicylic acid for patients with high thrombosis risk.

**Early onset**: Seizures, mental retardation.
**Late onset**: Psychiatric disorder, mental retardation.

**Early onset**: Microcephaly, hydrocephalus, cortical atrophy**, hypotonia, lethargy, developmental delay.
**Late onset**: Acute neurologic decompensation, extrapyramidal symptoms and tremor.

**Early onset**: Hypotonia, lethargy, apnea***, paresthesias***, feeding problems*** and eventually microcephaly.
**Late onset**: Progressive encephalopathy, ataxia, spasticity.

*Specific of CBS deficiency; ** Specific of cblC deficiency; *** Specific of MTHFR deficiency.

**Met:** methionine; **OHcbl:** hydroxycobalamin.

### Diagnosis

Markedly high tHcy (>50 µmol/L in children; tHcy >100 µmol/L in adults) together with increased Met and low cysteine in plasma are the classical biochemical features of HCU (Table 2). However, these biochemical abnormalities may be less pronounced in patients with milder forms of HCU or those taking vitamin supplements[22, 38, 39].

Confirmation can be made via the measurement of CBS activity (typically in fibroblasts). Since this method is not broadly available, molecular genetic analysis is most often used for confirmation of the diagnosis. DNA analysis can also be performed, especially in high-risk populations, for newborn screening and families with known CBS mutations. The human CBS gene is located at chromosome 21q22.3[40], and more than 200 disease-causing mutations have been identified [41]. [Stenson, 2017, The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research’, genetic diagnosis and next-generation sequencing studies][Stenson, 2017, The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research’, genetic diagnosis and next-generation sequencing studies][42] The most frequent mutations (p.Ile278Thr, p.Thr191Met and p.Gly307Ser) account for nearly half of the HCU alleles worldwide (http://cbs.lf1.cuni.cz/index.php). Prenatal diagnosis can be achieved by molecular genetic analyses or the extraction and culture of cells from amniotic fluid to measure CBS activity.[11, 42, 43]

Newborn screening has been performed, especially in countries with high incidences of HCU, such as Ireland and Qatar.[44, 45] The most common method is the measurement of Met in dried blood spots, but a high proportion of false negatives have been obtained by using this method.[46–48] The accuracy of Met to detect HCU is low since, in particular, the pyridoxine-responsive forms of HCU do not develop hypermethioninemia.
in the first days of life. In addition, other diseases can also lead to increased Met concentrations.[49] To increase sensitivity, reducing the cutoff for Met has been suggested.[49] In high-risk populations, the direct measurement of tHcy in DBS or analyses of CBS mutations should be performed.[50–52]

**Management**

CBS deficiency results in markedly increased plasma levels of tHcy and Met and low cysteine.[11,22] The main goal in HCU treatment is to reduce tHcy (<50 µmol/L for pyridoxine responsive and <100 µmol/L for non-responsive patients[13]). The first strategy in the treatment is to test whether the patient is pyridoxine responsive. Pyridoxal phosphate, the active form of pyridoxine, is a co-factor of CBS and high dose of pyridoxine administrations markedly decreases tHcy in approximately 50% of HCU patients.[14,53] Dosages from 100 to 500 mg/day in adults can be used. [9, 38] Typically, patients who are responsive to pyridoxine present delayed and less severe clinical symptoms and these individuals may not even require any additional treatment.[13,14] In addition to pyridoxine, oral folic acid supplementation (1 to 5 mg/day) should be administered because many patients are folate deficient at the time of diagnosis. Pyridoxine responsiveness should only be tested under normal folate levels.[9,39,54,55]

If pyridoxine plus folate is not able to reduce tHcy levels to the target values, then additional therapies should be used. A very efficient strategy to lower tHcy is dietary Met restriction. Met is an essential amino acid and a diet low in Met will result in a significant decline of tHcy. To meet protein and micronutrient requirements, a free-Met amino acid-based formula should be taken daily. The amount of Met tolerated per patient varies from 15 to 60 mg/kg/day.[56] Poor compliance to diet is common, especially in adults and late diagnosed patients.

Betaine acts in the remethylation route through a pathway independent of folate.[5] Oral betaine supplementation (6 - 9 g/day or 150 - 250 mg/kg/day) can reduce tHcy more than 70%, but this treatment results in an even more pronounced increase in Met. High levels of Met are acceptable, as long as this molecule does not exceed 1000 µmol/L, as levels higher may cause cerebral edema.[39,52,54]

Cobalamin (cbl) or vitamin B12 participates in the remethylation route together with folate, and its deficiency is common in HCU; thus, vitamin B12 should be monitored and supplemented when deficient.[9,39] N-acetylcysteine may be administered to increase cysteine levels.[13] For patients with high thrombosis risk (previous thromboembolic event or mutations in factor V), salicylic acid is recommended.[39]

Good metabolic control from the neonatal period and thereafter is capable to prevent the clinical manifestations of HCU.[14, 26, 57, 58] In late diagnosed patients, treatment can also significantly prevents morbidity and mortality.[44] Even when tHcy remained higher than the target values, a major reduction in vascular disease risk is observed in HCU patients.[20]

### Methylmalonic Aciduria and Homocystinuria, CblC Type

**Clinical Picture**

Methylmalonic aciduria and homocystinuria cblC type (MIM# 277400) is rare but remains the most common inborn error of cbl metabolism.[59] Newborn screening studies suggest that the incidence of cblC deficiency was higher than the previous estimate of 1/200,000 births.[60] A neonatal screening program in New York state estimates the incidence of cblC as approximately 1:100,000 live births.[61] and according to Han et al. (2015), the incidence of cblC was approximately 1:3,920 in Shandong Province, China.[62]

In 1969, the first case was reported by Mudd et al., concerning an infant with homocystinuria, methylmalonic aciduria, cystathioninemia, and hypomethioninemia. The infant died at 7.5 weeks of age. In vitro analysis identified a defect in the two reactions in which vitamin B12 derivatives function as coenzymes: 1) Met formation from 5MTHF and Hcy by MTR, and 2) the isomerization of methylmalonyl-CoA to succinyl-CoA (MUT) (Figure 2). Since vitamin B12 was present at normal concentrations in the liver, these authors concluded that the gene-determined defect involved the conversion of B12 to the active coenzymes.[63]

Individuals with cblC deficiency often suffer from a wide range of clinical complications, including developmental, metabolic, hematologic, neurologic, ophthalmologic and dermatologic findings.[64] Although considered a disease of infancy or childhood, patients can present at any time from the neonatal period to adulthood and can even be intrauterine affected. The disease has been classified into early-onset (infantile) and late-onset (noninfantile) forms.[65] Patients with early-onset disease, defined by the onset of symptoms before the age of one year, in general have severe systemic involvement. Symptoms include feeding difficulties, hypotonia, failure to thrive, seizures, microcephaly and developmental delay. Acidosis was observed in some patients. Progressive CNS findings were prominent and included hydrocephalus and neuroimaging evidence of cortical atrophy. Other systems became progressively involved. Nystagmus, pigmentary retinopathy, and decreased visual acuity were common. Hematological findings included thrombocytopenia, macrocytic anemia, megaloblastic marrow and/or hypersegmented polymorphonuclear neutrophils, leukopenia and neutropenia, probably all related to cellular folate deficiency. Also renal complications occur, which are not induced by increased MMA but are rather due to microangiopathy, resulting in hemolytic-uremic syndrome.[64] Mild facial anomalies have also been described in cblC patients; features included a long face, high forehead, large, floppy, and low-set ears, and flat philtrum. The morphologic characteristics became more evident after three years of age.[66]
The late-onset of the disease seems rarer than the early-onset form. In addition to mild or even no hematological abnormalities, the clinical course is characterized by behavioral and psychiatric disturbances and rapid mental deterioration with confusion and disorientation, dementia, delirium, and psychosis. Although its occurrence is rare, late-onset combined methylmalonic aciduria and homocystinuria, cblC type, should be considered when making a differential diagnosis in patients who present with neurological symptoms that are not consistent with common neurological diseases, especially when cognition, the pyramidal tract and peripheral nerves are involved. Taken together, patients can be easily misdiagnosed or even missed.

Rosenblatt et al. (1997) reviewed 50 cblC patients who could be classified into the two broad phenotypes: 44 patients had early-onset, and six patients had later-onset diseases. The 44 patients presented in the first year of life with feeding difficulties, hypotonia, developmental delay, seizures, pigmentary retinopathy, and anemia. The outcome is often poor, as approximately one-fourth of the patients died, and those who survived suffered in general from severe neurological impairment.

**Diagnosis**

CblC should be suspected when both tHcy and MMA are markedly elevated. CblC is a disorder of intracellular cbl metabolism caused by homozygous or compound heterozygous mutations in the **MMACHC** gene on chromosome 1p34. This disorder results in the impaired delivery of intracellular cbl to its two metabolically active forms, Mecbl and Adocbl. The decreased activity of these two enzymes causes elevations of tHcy and MMA as well as low-normal or reduced Met.[63,64] The overflow of Hcy into the transsulfuration pathway causes increases of cystathionine. In addition to overt B12 deficiency, other genetic defects in cbl metabolism, such as deficiency of cblD, cblF and cblJ, also result in increased of tHcy and MMA. The differential diagnosis is mainly based on gene analyses but may also be performed with functional complementation studies in cultured fibroblasts.

Because biochemical abnormalities are present in neonates, the diagnosis of cblC could be made by newborn screening, enabling the initiation of treatment prior to the development of notable pathology.[69] Key investigations for the diagnosis include measurements of plasma tHcy, MMA and Met and urinary organic acids. In acylcarnitine profiling, cblC patients often show increased propionylcarnitine (C3). Newborn screening can detect affected infants through decreased Met and elevated C3 or C3/C0 and C3/C2 ratios measured by tandem mass spectrometry (MS/MS). MMA and/or tHcy by MS/MS can be applied in second-tier analyses[61,70], although in theory, these analyses could be used directly in newborn screening.

Some common mutations are found in the **MMACHC** gene: c.271dupA (p.Arg91Lysfs*14), c.331C>T (p.Arg111Ter) and c.394C>T (p.Arg132Ter).[71,72] The p.Arg91Lysfs*14 and p.Arg111Ter mutations were associated with early-onset disease, while the p.Arg132Ter mutation is primarily associated with late-onset disease.[73,74] Wang et al. (2010) reported that the c.609 G>A (p.W203X) mutation, which results in a premature termination codon at amino acid residue 203 located in the C-terminal region of **MMACHC**, was detected in 39 of 46 patients, or 85% of alleles, making this mutation the most frequent in Chinese cblC patients.[70] Recently, it was reported a cblC patient who was heterozygous for the c.271dupA (p.Arg91Lysfs*14), at the **MMACHC** gene, and the c.515-1G>T, in the **PRDX1** gene. [75] Both variants were in trans. The **PRDX1** gene is located at the same locus than **MMACHC**, but transcribed in the opposite strand. The c.515-1G>T is considered an epimutation, since it leads to a hypermethylated sequence encompassing the promoter and first exon of **MMACHC** gene.

**Management**

The main goal in cblC treatment is to reduce plasma levels of MMA and tHcy and normalize levels of Met. Treatment typically consists of a combined approach that utilizes mega-dose vitamin B12 IM., preferably in the form of hydroxycobalamin (OHcbl). In a guideline for the diagnosis and management of remethylation disorders, Huemer et al. (2017) recommended a starting dose of 1 mg of OHcbl daily and administered parenterally.[76] Oral betaine is provided to enhances the remethylation via an alternative pathway and oral folinic acid ameliorates folate trapping.[67,71,77] Protein restriction to reduce MMA is contraindicated because it results in a great reduction of Met.[78]

In a retrospective analysis of 50 patients with cblC disease, Rosenblatt et al. (1997) described a shorter interval between the onset of symptoms and the diagnosis in patients who died, likely because these individuals were sicker and progressed more rapidly than those who survived. The overall mortality rate was 30% (13/44) in early-onset cblC, and the six patients with late-onset cblC survived with good neurological outcomes. Although treatment systemic symptoms improved, neurological and ocular impairments persisted. OHcbl was used in 80% of the patients, and patients treated with cyanocobalamin presented no biochemical improvement.[64]

In a review of published case reports and case series, Weisfeld-Adams et al. (2015) reported that maculopathy and nystagmus with abnormal vision affect a majority of children with early-onset cblC, and strabismus and optic atrophy present at relatively high frequency. The treatment fails to prevent ocular disease, even with prenatal treatment through OHcbl administered to the mother, despite apparently adequate plasma Met levels and moderately elevated plasma tHcy. This study suggested a correlation between the severity of the ocular phenotype and the biochemical phenotype.[79]

Andersson, Marble and Shapira (1999) described the clinical and biochemical features of eight cblC patients who were treated for an average of 5.7 years. The age at diagnosis was between 1 week and 11 months, and treatment consisted of OHcbl IM.
and daily oral carnitine supplementation. The earliest treated patient had one of the most severe developmental delay, showing that early treatment is no guarantee for better outcome. All patients presented with poor growth, feeding problems and/or seizures.[80]

More recently, in a retrospective study, Fischer et al. (2014) described 76 cblC patients with early-onset and 12 patients with late-onset diseases. The number of males affected was almost twice as high as the number of affected females. In early-onset group, 43 of the 76 patients presented symptoms in the first month of life. Parenteral OHcbl was prescribed to approximately 90% of the patients, but even after treatment, neurological and ophthalmological problems remained, such as developmental delay, seizures, failure to thrive, microcephaly and optic atrophy. Ten patients (11.4%) died, and these individuals were primarily non-treated with OHcbl.[71]

**Severe 5, 10-Methylenetetrahydrofolate Reductase (Mthfr) Deficiency**

**Clinical Picture**

Severe methylenetetrahydrofolate reductase (MTHFR) deficiency is inherited as an autosomal recessive metabolic disorder of folate metabolism caused by mutations in the MTHFR gene on chromosome 1p36.3.[81] Homozygous or compound heterozygous loss-of-function mutations in MTHFR result in systemic 5MTHF deficiency and so hampered Hcy remethylation (Figure 1). This rare disorder is associated with slow brain growth, severe neurological disability, and untimely death.[82]

Homocystinuria due to MTHFR deficiency (OMIM ID: 236250) was first described in 1972 by Mudd et al.[11,83] in a 16-year-old boy with muscle weakness, seizures and abnormal encephalographic signs, a 17-year-old girl with mental degradation and schizophrenia and her sister. These three patients had homocystinuria but normal levels of Met, normal CBS activity in fibroblasts and low MTHFR activity. Severe MTHFR deficiency is biochemically characterized by hyperhomocysteinemia, homocystinuria, increased cystathionine, and low or low-normal Met, in contrast with CBS deficiency, which presents with elevated Met. In cultured fibroblasts, residual activity is less than 20% of the mean control value.[76,82,84] (Table 2).

A classical presentation suggestive of MTHFR deficiency is a neonate with acute neurological distress, including generalized muscular hypotonia, feeding problems, failure to thrive, lethargy, apnea, and eventually microcephaly.[7,85] Patients may also present with late-onset disease during childhood and even in adulthood. The latter patients have a more variable picture, encompassing delayed developmental milestones, cognitive impairment and/or gait abnormalities, as well as mental degradation and progressive encephalopathy, compatible with myelopathy or ataxia, spasticity behavioral problems, an unspecific spectrum of psychiatric symptoms, and occasionally thrombosis. Megaloblastic and/or macrocytic anemia is typically absent.[7,85,86]

In contrast to the defects blocking MTR function, the block in the conversion of methylene-THF to methyl-THF does not result in the trapping of folates, as methyl-THF and does not interfere with the availability of reduced folates for purine and pyrimidine synthesis. This finding explains why patients do not have megaloblastic anemia and do not suffer from microangiopathy. [7] As the product of MTHFR methyl-THF is the circulating form of folate, MTHFR deficiency results in reduced folate levels, especially in the brain. Cerebral folate deficiency is a common finding in this inborn disorder.[87] Another interesting finding in the brain of patients with remethylation defects, compared to controls, is that choline, a precursor of betaine and so a source of methyl groups, seems deficient. The choline decreased levels is possibly a side effect of methyl groups depletion that should be produced by the transmethylation pathway.[88]

Age of presentation and clinical pattern correlate with residual enzyme activity.[7] In a review of 33 patients, Huemer et al. (2016) showed the median age at onset of symptoms was 1.25 months (mean 21; range 0.1 to 216 months). In 14 patients, the first symptoms were observed within the first month of life; and in another 11 patients, the symptoms were observed by the 6th month of life. The remaining five patients became symptomatic at the ages of 2, 5, 11, 13 and 18 years.[89]

In summary, MTHFR deficiency is a severe disease primarily affecting the CNS, likely due to the reduced availability of methyl-THF and Met, causing reduced cerebral methylation as suggested by decreased SAM levels in CSF.[90,91] MRI imaging of the brain often reveals white matter disease and brain atrophy.[89]

**Diagnosis**

Froese et al. (2016) reported more than 100 different mutations in over 170 patients with severe MTHFR deficiency. Most mutations in the MTHFR gene are restricted to one or two families.[92] The c.665C>T (p.Ala222Val) is a polymorphism leading to a thermolabile MTHFR variant with a propensity for monomer dissociation and flavin adenine dinucleotide binding loss, showing a 70% and 35% reduction of enzyme activity in lymphocytes in homozygotes and heterozygotes, respectively, when compared with wild-type controls.[93] Notably, this SNP does not cause severe MTHFR deficiency. However, this common variant is a fascinating gene-environment example because in homozygotes with low-normal folate levels, this variant hampers Hcy and folate homeostasis, causing moderate hyperhomocysteinemia. This variant has been associated with many common diseases, such as cardiovascular disease and neurodegenerative disorders, but so far only confirmed as a risk factor in neural tube defects.[84,94]

Neonatal screening for MTHFR deficiency is feasible by detecting a decreased Met and Met-to-phenylalanine ratio in dried blood spots, followed by analysis of tHcy. To what extent
are patients detected or missed remains obscure.[49] Direct measurement of MTHFR-specific activity can be performed in the liver tissue, leukocytes, lymphocytes and cultured fibroblasts. There is a rough inverse correlation between the specific activity of the reductase in cultured fibroblasts and clinical severity.[95]

**Management**

Untreated patients show progressive developmental delay and mental retardation, whereas some patients may also present with epilepsy and neurological disease (abnormal gait, spasticity).[7] The goal of treatment is to reduce plasma tHcy, normalize the levels of Met and folate, especially in CSF, and so presumably alleviate clinical symptoms. Treatment involves the administration (suggestive doses) of betaine (100–250 mg/kg/day in children and 5–20 g/day in adults) to provide an alternative pathway for Hcy remethylation. In addition, OHcbl (1-2 g/d) and folinic acid (400 mg/d) are prescribed. Pyridoxine, as a cofactor for CBS, may be administered to maximize the transsulfuration pathway and riboflavin as cofactor of the MTHFR enzyme. Met may be supplemented if its level remains low, despite treatment; in general, treatment improves the disease course in early-onset cases.[7, 82, 96, 97] Some studies have shown that treatment with folinic acid, Met, pyridoxine, and different cbl preparations but without betaine has generally been considered unsuccessful 7. In a systematic review, including 36 patients, the positive impact of early betaine treatment on the outcome in early-onset patients was shown: all five early treated patients survived with normal psychomotor development, while nine of ten non-treated and two of 21 late-treated patients died. In families with one or more deceased siblings, none of the treated but all of the untreated children died. Psychomotor development was impaired in all children with delayed treatment onset, despite the stabilization observed from the introduction of betaine treatment.[85]

Regarding the infantile forms, the only patients who have done well are those who were treated from birth. Early treatment with betaine following prenatal diagnosis has resulted in the best outcome.[98] Without treatment, these early-onset forms may rapidly progress to coma and potentially death by central respiratory failure. Since MTHFR deficiency is a potentially treatable disease, early diagnosis is crucial and treatment, in particularly betaine should be administered as early as possible.[92] Although single reports have described a benefit of treatment with folinic acid[99] or Met supplementation[96], the mainstay of treatment is betaine.[91]

**Conclusions**

Homocystinurias are a group of inborn errors of sulfur amino acid metabolism. Their joint manifestation is the accumulation of tHcy, however, the other sulfur amino acids show various and even invers profiles. CBS deficiency shows high Met with low cystathionine and cysteine. Whereas in the remethylation defects, Met is low-normal or decreased and cystathionine increased. Total cysteine in plasma is reduced in all homocystinurias because the elevated tHcy displaces cysteine from albumin, which binds the major fraction of tHcy and cysteine in plasma. At diagnosis, folate is typically low or (functionally) deficient in all homocystinurias. MTHFR deficiency blocks the production of methyl-THF, which is the circulation form of folate. In CBS deficiency, folate is often deficient at diagnosis probably due to the inhibition of MTHFR by the increased concentration of SAM. In cblC deficiency, a different mechanism kicks in: a dysfunctional MTR results in the accumulation of all folates as methyl-THF, which cannot be converted back to methylene-THF because MTHFR is physiologically none-reversible. These result in a functional folate deficiency despite that plasma folate may be normal or even increased because of the leakage of methyl-THF out of the cell. Intracellularly, folate is not available for the folate-dependent pathways. In particular, the synthesis of thymidylate and purine will be compromised, which will hamper essential cellular functions, especially in cells that rapidly divide, such as those in bone marrow. This functional folate deficiency occurs in any cell, which may explain why so many different organ systems can be affected in cblC patients, particularly when compared to the other remethylation defect of MTHFR deficiency, which mainly affects the CNS.

Some clinical findings were found in all homocystinurias, including vascular disease, developmental delay and seizures. However, the complications of CNS differ in a wide variety of presentations and severities and are apparently less pronounced in CBS. Moreover, patients with remethylation defects typically do not present ectopia lentis and bone disturbances, tall stature and osteoporosis. Whereas hematological alterations, such as megaloblastic anemia, thrombocytopenia neutropenia and life-threatening microangiopathy, are specific findings of cblC deficiency.

Treatment that lowers plasma tHcy in CBS deficient results in improved clinical outcome[13], by reducing the incidence of vascular events[19,20] or preventing mental retardation[57] and bone anomalies.[58] Remarkably, on treatment, the levels of plasma Hcy in general remained clearly elevated.[19, 100] Treated cblC patients have in general a marked reduction of tHcy, but neurological and ophthalmological problems usually remained.[71]
Abbreviations

Hcy: Homocysteine; CBS: Cystathionine beta-synthase; MTHFR: Methyleneetetrahydrofolate reductase; tHcy: Total homocysteine; Met: Methionine; ATP: Adenosine triphosphate; SAM: S-adenosylmethionine; SAH: S-adenosylhomocysteine; SAHH: S-adenosyl-L-homocysteine hydrolase; MTR: Methionine synthase; 5MTHF: 5-methyltetrahydrofolate; CSF: Cerebrospinal fluid; BHMT: Betaine–homocysteine methyltransferase; Mecbl: Methylcobalamin; Adocbl: Adenosylcobalamin; HCU: Classical homocystinuria; MMA: Methylmalonic acid; CNS: Central nervous; IQ: Intelligence quotient; DNA: Deoxyribonucleic acid; DBS: Dried blood spot; MUT: Methylmalonyl CoA mutase; Cbl: Cobalamin; C3: Propionylcarnitine; C0: Free carnitine; C2: Acetylcarnitine; MS/MS: Tandem mass spectrometry; IM: Intramuscular; OHcbl: Hydroxycobalamin; SNP: Single nucleotide polymorphisms; AR: Autosomal recessive; XL: X-linked recessive; Cy1: Cystathionine y-lase; THF: Tetrahydrofolate; SHMT: Serine-hydroxymethyltransferase; MMAA: Methylmalonic acid type A; MMAB: Methylmalonic Aciduria cblB Type; MMADHC: methylmalonic aciduria and homocystinuria type D; MMACHC: methylmalonic aciduria and homocystinuria type C protein; LMBRD1: gene that encodes a lysosomal membrane protein that may be involved in the transport and metabolism of cobalamin affected in cblF; ABCD4: gene ATP binding cassette subfamily D member 4 related to cblJ; HCF1: gene host cell factor C1 related to cblX; TCN2: transcobalamin 2; MTRR: gene methionine synthase reductase related to cblE.

Acknowledgment

National Coordination for Improvement of Education Personnel (CAPES-Brazil) and the National Counsel of Technological and Scientific Development (CNPq-Brazil).

Declaration of Conflict of Interests

The authors declare that they have no conflict of interests.

References


64. Rosenblatt DS, Aspler AL, Shevell MI, Pletcher BA, Fenton WA, Seashore MR. Clinical heterogeneity and


87. Knowles L, Morris AA, Walter JH. Treatment with Mefolate (5-Methyltetrahydrofolate), but Not Folic Acid or


